Scienture Holdings, Inc.

SCNX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-41.5M $9.1M $-17.8M $-3.5M $-5.3M $-2.5M $-284.4K $9.0K
Depreciation & Amortization $491.8K
Depreciation $2.0K $2.0K $19.4K $13.5K $7.4K $5.5K $5.0K
Amortization $453.8K $814.8K $44.1K
Stock-Based Compensation $2.1M $25.6K $29.7K $79.2K $64.2K $448.4K $176.4K
Net Cash from Operating Activities $-13.4M $-14.3M $-2.2M $-1.5M $-2.6M $-2.2M $141.8K $273.4K
Investing Activities
Capital Expenditures $12.0K $22.6K $37.5K
Business Acquisitions $344.5K
Net Cash from Investing Activities $27.6M $-275.7K $-427.8K $-22.6K $-37.5K $-332.3K $-265.3K
Financing Activities
Dividends Paid $14.9M
Stock Repurchases
Net Cash from Financing Activities $19.7M $-13.0M $1.4M $-35.2K $-208.2K $5.3M $2.2M $677.5K
Net Change in Cash $6.4M $307.8K $-1.1M $-2.0M $-2.8M $3.0M $2.0M $685.6K
Free Cash Flow $-14.3M $-2.6M $-2.3M
← Newer Page 1 of 2 Older →